MD Labs

MD Labs operates as an independent clinical laboratory, delivering specialized services in patient monitoring toxicology and pharmacogenetics testing. The company leverages advanced methodologies, including UPLC-MS/MS/MS for quantitative confirmatory toxicology and RT-qPCR technology for molecular diagnostics, to provide highly sensitive, accurate, and timely results. These capabilities enable comprehensive analysis and medication guidance for healthcare providers across the United States.

The company was co-founded by Matthew Rutledge, who serves as its President. With over 14 years of operation, the establishment of MD Labs was driven by the insight that patient care is paramount, necessitating reliable, accurate, and timely laboratory results to inform clinical decision-making. This foundational principle guides its commitment to excellence in clinical laboratory science.

MD Labs primarily serves healthcare professionals and practices nationwide, providing them with actionable data to guide clinical decisions. Its overarching vision is to improve clinical outcomes for patients by empowering providers with precise diagnostic information. The company continuously invests in research and technology to advance its testing capabilities and support evolving healthcare needs.